Effects of raloxifene hydrochloride on the endometrium of postmenopausal women

Boss, Susan M.; Huster, William J.; Neild, Julie A.; Glant, Michael D.; Eisenhut, Carol; Draper, Michael W.

doi:10.1016/s0002-9378(97)70091-7

Cited by 138 publications

(48 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These preclinical findings were supported by randomized, double-masked, placebocontrolled, multicenter clinical trials in healthy postmenopausal women wihtout osteoporosis [9,10], and in women with osteoporosis and at least one vertebral fracture [11]. Raloxifene treatment reduced bone resorption, increased bone mineral density, and had beneficial effects on serum lipids [12], without stimulation of the endometrium [13]. Therefore, raloxifene might be used for long-term prevention in postmenopausal women at risk for osteoporosis.…”

Section: Introductionmentioning

confidence: 87%

Treatment of Postmenopausal Women with Osteoporosis or Low Bone Density with Raloxifene

Meunier

Vignot

Garnero

et al. 1999

Osteoporosis International

View full text Add to dashboard Cite

Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to improved bone mineral density (BMD) and serum lipid profiles in healthy postmenopausal women. The objective of this study was to examine the effects of raloxifene on BMD, biochemical markers of bone metabolism and serum lipids in postmenopausal women with low bone density or osteoporosis. This Phase II, multicenter, 24-month, double-masked study assessed the efficacy and safety of raloxifene in 129 postmenopausal women (mean age +/- SD: 60.2 +/- 6.7 years) with osteoporosis or low bone density (baseline mean lumbar spine BMD T-score: -2.8). Women were randomly assigned to one of three treatment groups: placebo, 60 mg/day raloxifene-HCl (RLX 60) or 150 mg/day raloxifene-HCL (RLX 150) and concomitantly received 1000 mg/day calcium and 300 U/day vitamin D3. At 24 months, BMD was significantly increased in the lumbar spine (+3.2%), femoral neck (+2.1%), trochanter (+2.7%) and total hip (+1.6%) in the RLX 60 group compared with the placebo group (p < 0.05). The RLX 150 group had increases in BMD similar to those observed with RLX 60. A greater percentage of raloxifene-treated patients, compared with those receiving placebo, had increased BMD (p < 0.05). Serum bone-specific alkaline phosphatase activity, serum osteocalcin, and urinary type I collagen:creatinine ratio were significantly decreased in the RLX-treated groups, compared with the placebo group (p < 0.01). RLX 60 treatment significantly decreased serum levels of triglycerides, and total- and LDL-cholesterol levels (p < 0.01). The rates of patient discontinuation and adverse events were not significantly different among groups. In this study, raloxifene increased bone density, decreased bone turnover, and improved the serum lipid profile with minimal adverse events, and may be a safe and effective treatment for postmenopausal women with osteoporosis or low bone density.

show abstract

Section: Introductionmentioning

confidence: 87%

Treatment of Postmenopausal Women with Osteoporosis or Low Bone Density with Raloxifene

Meunier

Vignot

Garnero

et al. 1999

Osteoporosis International

View full text Add to dashboard Cite

show abstract

“…This is true even with high doses of raloxifene (up to 600 mg/day). 10 In preclinical studies, raloxifene has antiproliferative effects both in vitro and in vivo in experimental breast carcinoma models, including dimethylbenzanthracene-induced tumors in rats 11 and Michigan Cancer Foundation (MCF)-7 human breast xenografts in nude mice. 12 In addition, raloxifene reduced both tumor incidence and tumor volume in the rat nitrosomethylurea-induced chemoprevention model of mammary carcinogenesis.…”

mentioning

confidence: 99%

Effects of high dose raloxifene in selected patients with advanced breast carcinoma

Gradishar

Glusman

Lü

et al. 2000

Cancer

View full text Add to dashboard Cite

“…Raloxifene appears to lack proliferative effects on endometrial tissue. Data from both animal and human studies demonstrate that raloxifene has minimal effects on the uterus and causes no significant changes in the histologic appearance of the endometrium (Boss et al 1997). Two six-month studies involving a total of 969 postmenopausal women showed that endometrial thickness did not differ between women receiving raloxifene (30 to 150 mg per day) and those receiving placebo (Delmas et al 1997).…”

Section: Raloxifenementioning

confidence: 99%

Reducing the Risk of Endometrial Cancer in Patients Receiving Selective Estrogen Receptor Modulator (SERM) Therapy

Vogel¹

2012

Cancer of the Uterine Endometrium - Advances and Controversies

View full text Add to dashboard Cite

Effects of raloxifene hydrochloride on the endometrium of postmenopausal women

Cited by 138 publications

References 13 publications

Treatment of Postmenopausal Women with Osteoporosis or Low Bone Density with Raloxifene

Treatment of Postmenopausal Women with Osteoporosis or Low Bone Density with Raloxifene

Effects of high dose raloxifene in selected patients with advanced breast carcinoma

Reducing the Risk of Endometrial Cancer in Patients Receiving Selective Estrogen Receptor Modulator (SERM) Therapy

Contact Info

Product

Resources

About